New metrics for CXL
Refining measurement should lead to better treatment. Read article and watch video.


Leigh Spielberg
Published: Tuesday, May 16, 2017

Progression rate indices are needed that rely less on macroscopic dataSo, what’s new? Dr Touboul finds the development of pachymetry mapping promising. “Using OCT, corneal structure can be analysed by separating stromal changes and epithelial compensation, making this modality very interesting. The dominant method to rate progression is topographical and tomographical analysis,” said Dr Touboul. This is strongly correlated with worsening of keratoconus in terms of biomechanics, retinal image quality as defined by the point spread function, and with quality of life. Indeed, the decision to intervene in order to halt progression surgically is best made based on this morphological metric, he said. But clinicians cannot focus too much on a single metric. Defining keratoconus progression rates requires the analysis of the entire patient’s profile. There is no magic number to determine therapeutic indications, he emphasised. David Touboul: david.touboul@chu-bordeaux.fr
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.